Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic Acid as Adjuvant Therapy in Type 2 Diabetes
NCT05902468Phase 3Unknown
- Sponsor
- Tanta University
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ursodeoxycholic acid in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tanta University. Primary endpoint: Glycemic control at 12 weeks. Status: unknown.
02
Drugs
ursodeoxycholic acid
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05902468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902468.